YU6304A - Atenuirani virus besnila sa nukleoproteinskom mutacijom u mestu za fosforilaciju za vakcinaciju protiv besnila i gensku terapiju u cns-u - Google Patents

Atenuirani virus besnila sa nukleoproteinskom mutacijom u mestu za fosforilaciju za vakcinaciju protiv besnila i gensku terapiju u cns-u

Info

Publication number
YU6304A
YU6304A YU6304A YUP6304A YU6304A YU 6304 A YU6304 A YU 6304A YU 6304 A YU6304 A YU 6304A YU P6304 A YUP6304 A YU P6304A YU 6304 A YU6304 A YU 6304A
Authority
YU
Yugoslavia
Prior art keywords
virus
mutant
mutation
methods
viral
Prior art date
Application number
YU6304A
Other languages
English (en)
Inventor
Fang Fu Zhen
Original Assignee
The University Of Georgia Research Foundation Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Georgia Research Foundation Inc. filed Critical The University Of Georgia Research Foundation Inc.
Publication of YU6304A publication Critical patent/YU6304A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Obezbeden je mutantni virus koji sadrzi mutaciju u mestu za fosforilaciju u okviru jednog ili vise proteina virusa, mutacija koja dovodi do atenuacije virusa, i tako se od njega moze proizvesti poboljsana kompozicija vakcine. Ovaj pronalazak se takode odnosi i na kompozicije vakcine koje sadrze mutantni virus, kao i metode za indukovanje imunog odgovora, i zastitu sisara od infekcije virusom besnila. Takode u pronalasku su ukljucene metode za proizvodnju mutantnih virusa i mutantnih viralnih proteina, ukljucujuci proizvodnju mutantnog virusa u domacinskoj celiji koja proizvodi ili cak proizvodi u visku divlji analog mutantnog viralnog proteina, koji komplementira druge viralne proteine tako da je optimizovana proizvodnja mutantnih virusnih cestica. Ovaj pronalazak takode ukljucuje one domacinske celije u kojima je optimizovana viralna produkcija, kao i kompozicije vakcina ukljucUjuci viralne proteine, same ili u kombinaciji sa intaktnim virusom, i metode za indukovanje imunog odgovora ili zastitu sisara od infekcije upotrebom istih. Takode su u ovaj pronalazak ukljuceni vektori za dostavu gena u celiju humanog ili sisarskog porekla, kao i metode za njihovu dostavu.
YU6304A 2001-07-20 2002-07-22 Atenuirani virus besnila sa nukleoproteinskom mutacijom u mestu za fosforilaciju za vakcinaciju protiv besnila i gensku terapiju u cns-u YU6304A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33135401P 2001-07-20 2001-07-20

Publications (1)

Publication Number Publication Date
YU6304A true YU6304A (sh) 2006-08-17

Family

ID=23293602

Family Applications (1)

Application Number Title Priority Date Filing Date
YU6304A YU6304A (sh) 2001-07-20 2002-07-22 Atenuirani virus besnila sa nukleoproteinskom mutacijom u mestu za fosforilaciju za vakcinaciju protiv besnila i gensku terapiju u cns-u

Country Status (17)

Country Link
US (3) US6706523B2 (sh)
EP (1) EP1434862A4 (sh)
JP (1) JP2005510249A (sh)
KR (1) KR20040029377A (sh)
CN (1) CN100346826C (sh)
AU (1) AU2002365029A1 (sh)
BR (1) BR0211342A (sh)
CA (1) CA2454397A1 (sh)
CO (1) CO5560623A2 (sh)
HR (1) HRP20040078A2 (sh)
HU (1) HUP0500722A2 (sh)
MX (1) MXPA04000589A (sh)
NZ (1) NZ531025A (sh)
PL (1) PL371967A1 (sh)
WO (1) WO2003046506A2 (sh)
YU (1) YU6304A (sh)
ZA (1) ZA200400340B (sh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0500722A2 (hu) * 2001-07-20 2005-11-28 The University of Georgia Research Foundation, Inc@Á Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén
BRPI0509683A8 (pt) 2004-04-09 2015-12-22 Wyeth Corp Vírus de estomatite vesicular geneticamente modificado, vetor de vírus da estomatite vesicular geneticamente modificado, composição imunogênica, e, métodos para imunizar um hospedeiro mamífero contra infecção bacteriana e contra infecção viral
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
CN100341571C (zh) * 2005-09-16 2007-10-10 孙介光 一种治疗肿瘤的药物及该药物在制备治疗肿瘤药物中应用
EP1945780B1 (en) * 2005-10-14 2015-09-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Rabies virus vector systems and compositions and methods thereof
CN101384278A (zh) * 2005-12-14 2009-03-11 乔治亚大学研究基金公司 狂犬病疫苗
WO2008054544A2 (en) * 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
CN102159240B (zh) * 2008-09-17 2014-12-24 美国政府健康及人类服务部，疾病控制和预防中心 基于狂犬病毒的重组免疫避孕组合物及其使用方法
US10849975B2 (en) 2011-02-03 2020-12-01 Thomas Jefferson University Multivalent vaccines for rabies virus and filoviruses
CN102205119B (zh) * 2011-04-12 2012-05-30 广州市华南农大生物药品有限公司 狂犬病灭活抗原及其制备方法
KR101479668B1 (ko) * 2012-07-31 2015-01-12 대한민국 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물
CN106929482A (zh) * 2015-12-31 2017-07-07 北京大学 定点突变的流感病毒、其活疫苗及其制备方法和应用
KR20170002590U (ko) 2016-01-08 2017-07-18 최문규 제조와 포장이 용이한 일회용 위생장갑
EP4104854A3 (en) 2016-04-04 2023-03-08 The United States of America as represented by the Secretary of the Department of Health and Human Services Multivalent vaccines for rabies virus and coronaviruses
WO2017200790A1 (en) * 2016-05-20 2017-11-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Real-time reverse transcriptase-polymerase chain reaction assay with modified probe for the diagnosis of rabies viruses and other lyssaviruses
GB201706945D0 (en) * 2017-05-02 2017-06-14 Medical Res Council Self-inactivating viral vector
US20230398201A1 (en) * 2020-11-03 2023-12-14 Thomas Jefferson University Gene shuffled lyssavirus vaccine
EP4263825A1 (en) * 2021-02-19 2023-10-25 Beam Therapeutics, Inc. Recombinant rabies viruses for gene therapy
CN114957408B (zh) * 2021-02-24 2024-04-23 东莞博盛生物科技有限公司 一种狂犬病毒的preG改性蛋白及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2693655B1 (fr) * 1992-07-20 1994-10-14 Virbac Vaccin antirabique avirulent.
US5583735A (en) * 1994-01-18 1996-12-10 Hollingsead International, Inc. Aircraft video monitor deployment and retraction apparatus
DK0702085T4 (da) * 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6719881B1 (en) 1998-09-22 2004-04-13 Charles R. Hunter Acid colloid in a microparticle system used in papermaking
ID28968A (id) * 1998-11-27 2001-07-19 Akzo Nobel Nv Mutan-mutan virus rabies yang dilemahkan dan stabil, serta kehidupan vaksin daripadanya
HUP0500722A2 (hu) * 2001-07-20 2005-11-28 The University of Georgia Research Foundation, Inc@Á Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén

Also Published As

Publication number Publication date
US20030099671A1 (en) 2003-05-29
HRP20040078A2 (en) 2004-08-31
CN1635905A (zh) 2005-07-06
WO2003046506A2 (en) 2003-06-05
CN100346826C (zh) 2007-11-07
US7419816B2 (en) 2008-09-02
US20040208900A1 (en) 2004-10-21
US6706523B2 (en) 2004-03-16
US7544791B2 (en) 2009-06-09
HUP0500722A2 (hu) 2005-11-28
BR0211342A (pt) 2005-05-03
KR20040029377A (ko) 2004-04-06
JP2005510249A (ja) 2005-04-21
ZA200400340B (en) 2004-08-18
NZ531025A (en) 2005-08-26
CO5560623A2 (es) 2005-09-30
US20070178555A1 (en) 2007-08-02
EP1434862A4 (en) 2005-04-06
MXPA04000589A (es) 2005-06-17
AU2002365029A1 (en) 2003-06-10
PL371967A1 (en) 2005-07-11
EP1434862A2 (en) 2004-07-07
WO2003046506A3 (en) 2004-04-22
CA2454397A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
YU6304A (sh) Atenuirani virus besnila sa nukleoproteinskom mutacijom u mestu za fosforilaciju za vakcinaciju protiv besnila i gensku terapiju u cns-u
CA2334857A1 (en) Interferon inducing genetically engineered attenuated viruses
US10925946B2 (en) Vaccination methods
Thiele et al. Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways
EE200300332A (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin
Cervantes-Barragan et al. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity
Del Fresno et al. The bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity
US20210205436A1 (en) Recombinant mopeia virus and vaccine platform
WO2000061737A3 (en) Production of attenuated negative stranded RNA virus vaccines
Khairkhah et al. Immunological investigation of a multiepitope peptide vaccine candidate based on main proteins of SARS-CoV-2 pathogen
Khan et al. Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein
Keshavarz et al. Induction of protective immune response to intranasal administration of influenza virus‐like particles in a mouse model
MX2022016287A (es) Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas.
MX2022016337A (es) Vectores de hvt recombinantes que expresan hemaglutinina de influenza y composiciones inmunogenicas, su produccion y usos.
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
Abdulhaqq et al. Vaccine-mediated inhibition of the transporter associated with antigen processing is insufficient to induce major histocompatibility complex E-restricted CD8+ T cells in nonhuman primates
JPWO2007023725A1 (ja) 遺伝子ワクチン
Basirnejad et al. Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
TR200101445T2 (tr) Kararlı, zayıflatılmış kuduz virüsü mutantları ve bu mutantların canlı aşıları
Mei et al. Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate
WO2000077177A3 (en) Isolation of a human retrovirus
EP0542895B1 (en) Cross-reactive influenza a immunization
CA1270438A (en) Influenza vaccine
US20230127808A1 (en) Ad7-vectored vaccine for preventing sars- cov-2 infection